

May 1, 2014

Board of Directors  
Hemophilia Alliance  
1758 Allentown Road, No. 183  
Lansdale, Pennsylvania 19446


Dear Board Members,

Octapharma USA is pleased to provide its input into an important issue regarding continuing access to life-saving blood coagulation factor for Florida Medicaid beneficiaries. As a relatively recent entrant into the U.S. coagulation market, Octapharma is committed to the core principle of ensuring access to all approved therapies for patients who need them. As applied to the specific case of Florida Medicaid, we believe that patients with bleeding disorders would benefit from having multiple providers of factor whether from a hemophilia treatment center or from specialty pharmacy.

Octapharma USA recognizes the importance of all providers and market participants who pay a role in delivering factor products to the patients who need them. Chief among the providers is the federally-funded hemophilia treatment (HTC) network – a jointly managed program of the Maternal Child and Health Bureau and the Centers for Disease Control and Prevention. Over the years CDC data has shown that hemophilia treatment centers are responsible for a 40% decline in mortality and morbidity for HTC patients, *i.e.*, patients who visit the hemophilia treatment center at least once annually.

As it continues to expand its repertoire of coagulation therapies available to patients in the U.S., Octapharma USA looks forward to working with the bleeding disorders community and with providers such as the HTC network. Together, we will work towards the goal of ensuring that patients with bleeding disorders have access to their life-saving therapies irrespective of source be it a specialty pharmacy or directly through a hemophilia treatment center.

Yours truly,



Flemming Nielsen  
President, Octapharma USA, Inc.  
Member of the Board, Octapharma A.G.

Octapharma USA, Inc.  
Waterfront Corporate Center  
121 River Street, 12th Floor  
Hoboken, NJ 07030  
USA

---

phone: (201) 604 -1130  
Fax: (201) 604 -1131  
[www.octapharma.com/usa](http://www.octapharma.com/usa)

---